4D Molecular Therapeutics FDMT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's cash & equivalents?
- 4D Molecular Therapeutics (FDMT) reported cash & equivalents of $72.49M in Q1 2026.
- How has 4D Molecular Therapeutics's cash & equivalents changed year-over-year?
- 4D Molecular Therapeutics's cash & equivalents decreased by 45.7% year-over-year, from $133.53M to $72.49M.
- What is the long-term trend for 4D Molecular Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's cash & equivalents has grown at a -26.3% compound annual growth rate (CAGR), from $276.73M to $60.24M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.